Navigation Links
Reportlinker Adds IP Overview - "Monoclonal Antibodies against digestive system cancers" Patent Landscape 2010
Date:9/21/2010

NEW YORK, Sept. 21 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

IP Overview – "Monoclonal Antibodies against digestive system cancers" Patent Landscape 2010

http://www.reportlinker.com/p0296354/IP-Overview-–-"Monoclonal-Antibodies-against-digestive-system-cancers"-Patent-Landscape-2010.html

In order to fight digestive system cancers, monoclonal antibody-based therapies have recently reinforced the range of already marketed treatments (mostly constituted of small molecules) and are generating important revenues. Four antibodies have already been approved but new ones are still needed. Many players are therefore trying to position themselves on this sector. This has resulted in an active patent policy that has nevertheless reached a plateau since 2005.

The present report analyses the patent environment and highlights the various monoclonal antibodies that have been developed to diagnose and treat oesophageal, gastric, bile duct, gastro-intestinal, colorectal, hepatic, pancreatic and anal cancers. The major trend is the development of human immunoconjugates against colorectal cancers by targeting growth factor receptors. Although this sector is surrounded by Roche and its subsidiaries, other players, and especially big pharma and biotech companies, continue to develop antibodies targeting new antigens and/or having new properties.

In this competitive sector driven by an important market and where 3000 patent families have been filed, this study « IP Overview – Monoclonal antibodies against digestive system cancers» provides you with a comprehensive panorama of the intellectual property landscape and helps you:

- Position your company's R&D and IP Portfolio

- Identify key inventors and key players involved in the development of new monoclonal antibodies

- Understand the collaboration networks and their dynamics

- Discover new trends and emerging topics

Please note that a three months access to the full patent database is also included

Table of contents Brief outline of the technologyGeneralitiesBrief outline of the market - 2009

Patent query

Brief outline of the pipeline - 2010

Evolution of patent filings (1988-2008)

Evolution of the number of applicants

Industrial & institutional filings over time

Map of extensions

Map and evolution of priority filings

Evolution and location of patent filingsMain applicants on the entire period (1988-2008)

Part of the portfolio hold by the first 10 applicants

Breakdown of filings of the main industrial/institutional applicants over time

Main applicants in the last 4 years (2005-2008)

Main co-filings between applicants

Analysis of patent applicantsAnalysis of inventors

List of the main inventors

Main research teams

Emerging inventors

Topics of patent filingsBreakdown of the portfolio (for each breakdown is presented the evolution of filings

and the positioning of institutional applicants, industrial applicants and inventors)

1/Type of monoclonal antibodies

2/Targets of monoclonal antibodies

2.1/Growth factor receptors

2.2/Molecules involved in cell adhesion

2.3/Other targets

3/Type of digestive system cancers targeted by mAbs

Focus on ROCHEOrganization chart

Distribution and evolution of patent filings by subsidiaries

Filing policy

Topics of patent applications

Comments

Citation & Extension AnalysisList of the most cited patents and patent applications

Positioning of patent applications portfolio via citation analysis

Most extended patents

Coverage rate classification

ConclusionAppendicesmAbs clinical trials by company

Applicants/Affiliates

To order this report:Biological Therapy Industry: IP Overview – "Monoclonal Antibodies against digestive system cancers" Patent Landscape 2010

Biological Therapy Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!CONTACT:  Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Electrophysiology Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
2. Reportlinker Adds Prosthetic Heart Valves - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
3. Reportlinker Adds U.S. Market for Cardiac Rhythm Management, Electrophysiology and Ablation Devices 2010
4. Reportlinker Adds Canadian Dental Market Overview & Dentist Survey 2010 (Implants, Prosthetics, Imaging & CAD/CAM)
5. Reportlinker Adds ENT Devices Market Outlook in Argentina to 2016 - Hearing Aid Devices and Implants and Diagnostic Devices
6. Reportlinker Adds Healthcare IT Market Outlook in China to 2016 - Hospital Information Systems and Medical Imaging Information Systems
7. Reportlinker Adds Interventional Cardiology Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
8. Reportlinker Adds Clinical Trial Patient Recruitment: Accelerate Enrollment, Increase Retention and Reduce Costs
9. Reportlinker Adds Global Renal Dialysis Equipment Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
10. Reportlinker Adds Global Coronary Stents Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
11. Reportlinker Adds Cardiovascular Surgery Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... N.J. , March 29, 2017  Novartis ... Administration (FDA) has accepted the company,s Biologics License ... CTL019 (tisagenlecleucel-T), an investigational chimeric antigen receptor T ... pediatric and young adult patients with B-cell acute ... submission by Novartis for a CAR-T. The priority ...
(Date:3/29/2017)... -- The Global Health Innovative Technology Fund (GHIT Fund), ... infectious diseases around the globe, today announced 11 ... deliver a range of new innovative therapies for ... This latest round of targeted support includes funding ... pediatric formulation of a drug considered the gold ...
(Date:3/29/2017)... March 29, 2017 Optometrists have staunchly ... the highest standard in quality and care for ... its objective Wavefront-driven refraction technologies and process to ... enables an unprecedented level of refraction and correction ... relegated to Topgun Navy fighter pilots, but now ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... During the last week of March, Chad ... to eligible individuals in the local community. , Colon cancer is the second ... detect colon cancer while it is small, confined and easier to treat. If you ...
(Date:3/29/2017)... ... 29, 2017 , ... In the United States alone, up to 36% of ... types of metastatic brain tumors(3). Though most meningiomas are benign, metastatic brain tumors are ... more effective treatment options, the San Diego Gamma Knife Center offers a ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... Full Contact ... founder of Pet Protect Law that assists dog owners in creating legally-enforceable ... new owners in taking the natural next step to protect their new companion. Says ...
(Date:3/29/2017)... ... March 30, 2017 , ... CHARM CITY RUN WELCOMES MERCY MEDICAL CENTER AS ... Medical Center will serve as the official title sponsor of the Baltimore Women’s Classic, ... 2017, thousands of women will walk or run the course around the Baltimore Inner ...
(Date:3/29/2017)... (PRWEB) , ... March 30, 2017 , ... Sublime Naturals ... "Spice of Life" or "Wonder Spice", it has been used for thousands of years. ... the East," says Heshelow, author of " Turmeric: How to Use it For Your ...
Breaking Medicine News(10 mins):